title: Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
abstract: A 1-year trial with entecavir plus adefovir resulted in a rate of virological response (VR) higher than that seen with lamivudine plus adefovir in multiple-drug-refractory chronic hepatitis B (CHB) patients. This extension study enrolled 89 of 90 patients who completed a 52-week randomized trial comparing treatment with entecavir plus adefovir (EA) to treatment with lamivudine plus adefovir (LA). At the baseline of the original study, all patients had lamivudine-resistant hepatitis B virus (HBV) and serum HBV DNA > 2,000 IU/ml despite prior lamivudine plus adefovir therapy. Of the 89 enrolled patients, 45 initially randomized to receive entecavir plus adefovir and the other 44 randomized to receive lamivudine plus adefovir received entecavir plus adefovir for an additional 52 weeks (EA-EA and LA-EA, respectively). The proportions of patients with a VR (serum HBV DNA < 60 IU/ml) gradually increased in both groups and were comparable at week 104 (42.2% in the EA-EA group and 34.1% in the LA-EA group; P = 0.51). The mean reductions in serum HBV DNA from baseline in the two groups were similar (-2.8 log10 IU/ml and -2.8 log10 IU/ml, respectively; P = 0.87). At week 104, the number of patients who retained the preexisting HBV mutants resistant to adefovir or entecavir had decreased from 8 to 2 in the EA-EA group and from 15 to 6 in the LA-EA group (P = 0.27). Both study groups had favorable safety profiles. In conclusion, up to 104 weeks of entecavir plus adefovir treatment was associated with a progressive VR, a decrease of levels of preexisting drug-resistant mutants, and no selection for additional resistance mutants of HBV in multiple-drug-refractory CHB patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT01023217.).
authors: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. imys@amc.seoul.kr
authors: Young-Suk
authors: YS
authors: Lim
authors: Ji-Young
authors: JY
authors: Lee
authors: Danbi
authors: D
authors: Lee
authors: Ju Hyun
authors: JH
authors: Shim
authors: Han Chu
authors: HC
authors: Lee
authors: Yung Sang
authors: YS
authors: Lee
authors: Dong Jin
authors: DJ
authors: Suh
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004279:DNA, Viral; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; C053001:adefovir; D000225:Adenine
references: Gut. 2011 Feb;60(2):247-54
references: 21036792
references: J Hepatol. 2010 Sep;53(3):449-54
references: 20646776
references: Hepatology. 2010 Jan;51(1):73-80
references: 19998272
references: Hepatology. 2007 Feb;45(2):307-13
references: 17256746
references: J Hepatol. 2006 Oct;45(4):529-38
references: 16879891
references: N Engl J Med. 2004 Oct 7;351(15):1521-31
references: 15470215
references: Lancet. 2006 Sep 9;368(9539):896-7
references: 16962862
references: Hepatology. 2006 Jun;43(6):1385-91
references: 16729316
references: Hepatology. 2009 Oct;50(4):1064-71
references: 19637288
references: Hepatology. 2009 Sep;50(3):743-51
references: 19585616
references: Hepatology. 2010 Sep;52(3):886-93
references: 20683932
references: Hepatology. 2004 Oct;40(4):883-91
references: 15382125
references: Antimicrob Agents Chemother. 2012 Jun;56(6):2941-7
references: 22430972
references: Gastroenterology. 2004 Jan;126(1):91-101
references: 14699491
references: Gastroenterology. 2007 Nov;133(5):1445-51
references: 17983801
references: Gastroenterology. 2006 Mar;130(3):678-86
references: 16530509
references: Antivir Ther. 2012;17(1):53-60
references: 22267469
references: Antivir Ther. 2011;16(1):77-87
references: 21311111
references: Antivir Ther. 2007;12(3):355-62
references: 17591025
references: Hepatology. 2010 Feb;51(2):422-30
references: 20049753
references: Hepatology. 2011 Mar;53(3):763-73
references: 21374657
references: J Hepatol. 2010 Apr;52(4):493-500
references: 20185191
references: JAMA. 2006 Jan 4;295(1):65-73
references: 16391218
references: J Gastroenterol Hepatol. 2014;29(7):1485-93
references: 25587617